Floatz logo

Factor Viii Inhibitor Bypassing Fraction

Severe Hemophilia A

Skane University HospitalmixtureN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Severe Hemophilia A cohort.

Asset / SponsorPhaseRating
Human Antihemophilic Factor/Von Willebrand Factor Complex
AryoGen Pharmed Co.
Phase 4BBB
Human-Cl Rhfviii
Octapharma
Phase 3BBB
Emicizumab
Chulalongkorn University
Phase 4BBB
Rfviiifc
Bioverativ Therapeutics Inc.
Phase 3BB
Alphanate Sd/Ht
Grifols Biologicals, LLC
Phase 4BB

View all 21 →

Same molecule, other indications

Factor Viii Inhibitor Bypassing Fraction is also rated in:

hemophilia AActive
BBB
Indicative · Phase 4
72 / 100
View asset →
hemophiliaDormant
BB
Indicative · Phase 3
68 / 100
View asset →
hemophilia BDormant
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →